Systemic alpha‐interferon therapy of multiple sclerosis

摘要: A randomized, double-blind, placebo-controlled crossover study tested the efficacy of natural alpha interferon in altering exacerbating-remitting MS. Twenty-four patients with frequent exacerbations were treated for 6-month periods, beginning either 5 × l06 IU daily or placebo. washout period followed each treatment. Exacerbation rates reduced during and placebo phases compared pre-study rates; a greater reduction occurred on interferon, particularly following placebo, possibly reflecting learning phenomenon. Fifteen strictly course had fewer milder those whereas 9 progressive component continued to have active disease. These results suggest that might reduce certain indicate guidelines future trials